Skip to content
DataLookout
Menu

NCT02989636

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 16 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 32 words Show 4 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Nov 2026 to Sep 2, 2026
    • Study description revised
    • Site details revised at 1 of 2 sites
  2. Minor Primary completion date changed from estimate of Nov 2024 to Apr 24, 2024
    • Study completion date: Nov 2024 to Nov 2026
    v22
  3. Notable Primary and study completion dates: Nov 2023 to Nov 2024v20
  4. Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 33 to confirmed 21
    v17
  5. Minor Trial status: Recruiting to Enrolling by Invitation
    • Site details revised at 2 of 2 sites
    v16
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Primary and study completion dates: Mar 2022 to Nov 2023v14
  2. Notable Eligibility criteria expanded, about 50 words
    • Site contacts updated at 1 of 2 sites
    v12
  3. Notable Trial status: Active, Not Recruiting to Recruiting
    • Eligibility criteria expanded, about 50 words
    • Site details revised at 2 of 2 sites
    v11
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v10
  5. Notable Primary and study completion dates pushed to Mar 2022v9
  6. Minor Site contacts updated at 1 of 2 sites
    • Collaborators: 1 to 3
    v6
  7. Minor Site details revised at 1 of 2 sitesv5
  8. Notable Eligibility criteria expanded, about 11 wordsv4
  9. Notable Eligibility criteria shortened, about 9 wordsv3
  10. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date: Jan 2017 to Mar 10, 2017
    • Primary completion date: Jan 2020 to Mar 2020
    • Study completion date: Mar 2021
    • Site details revised at 2 of 2 sites
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Timeframe: Up to 12 weeks after initial dose of nivolumab

Arms and interventions

Arm I (nivolumab)Experimental

Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.

Arm II (nivolumab, SRS)Experimental

Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.

Other: Laboratory Biomarker Analysis

Biologicals: Nivolumab

Radiation: Stereotactic Radiosurgery

Sites

2 sites in 1 country